Introduction
The modification of pharmacologically active agents via specific attachment of generic "cytotopic" reagents based on the myristoyl-electrostatic switch (1) has been described elsewhere (2) . The term "cytotopic" is used here to mean a chemically modified agent that acts primarily at the surface (topos) of a cell (cytos). The approach has found particular use with regulators of complement activation, notably fragments of CR1 (CD35) (3), CD55 (4) , and CD59 (5) . Cytotopic membranelocalizing groups are relatively hydrophilic despite containing at least one membrane-insertive alkanoyl group, and conjugates of active agents with such groups remain sufficiently water soluble to be used as (bio)pharmaceuticals (2) . Further, such agents can be applied locally to organs or tissues where they are retained and function in a regioselective fashion.
Experimental and clinical experience with the CR1 derivative Mirococept (APT070) has shown that this agent can be delivered to kidneys (6, 7) and, in one case, human liver (8) via ex vivo perfusion, resulting in uptake by the microvasculature of the organ and a consequent enhanced complement inhibitory activity on reperfusion of the implanted graft. The process of antibody-mediated rejection (AMR) involves not only complement activation but also the direct effects of high levels of antidonor MHC class I and class II antibodies, which activate donor endothelium promoting intravascular thrombosis; in the florid form seen in hyperacute AMR, this can cause graft necrosis.
Detailed histological evaluation of large animal cardiac allografts and xenografts (and human allografts) undergoing AMR suggests that this thrombotic process, beginning in venules, is an early feature of the rejection process (9) . In AMR associated with blood groupincompatible renal transplantation, it was evident that glomerular fibrin deposition was an early manifestation of humoral rejection, appearing before graft dysfunction in some cases (10) . The major benefit of inhibiting thrombin generation after xenotransplantation was shown by our group several years ago using transgenic mouse hearts transplanted into rats, following which the manifestations of AMR were completely abolished, though notably the hearts were still susceptible to cell-mediated rejection (11) . In xenografts, this phenomenon can arise because xenogeneic endothelial cells are capable of direct conversion of prothrombin to active thrombin (12, 13) , the central protein in the coagulation cascade triggered via a number of different mechanisms, independently of AMR (14) . There are indications that a similar complementindependent thrombosis plays a prominent role in rodent AMR models, promoted by molecules such as fgl-2 (15, 16) , suggesting that targeting coagulation processes directly inside allografts might have a similar impact as we have shown in xenografts. We were, therefore, interested in generating cytotopic anticoagulants, particularly thrombin inhibitors, for use inside organs, specifically to inhibit thrombin generation after transplantation.
To target coagulation, we constructed a membraneassociated anticoagulant based on a minimized form of hirudin (a well-known thrombin inhibitor that is naturally occurring in the salivary glands of leeches). The principle behind the resulting synthetic cell-tethered inhibitor (thrombalexin-1 [TLN-1]) is similar to the complement inhibitor Mirococept (2,3). TLN-1 binds the phospholipid bilayer using a combination of a bismyristoyl hydrophobic structure (5) and a lysine-rich sequence, which binds negatively charged phospholipid headgroups. TLN-1, like hirudin and its synthetic derivative hirulog, interacts with thrombin at the active site and at the fibrinogen-binding exosite I (17) .
In this study, we report the generation and evaluation of TLN-1 in an appropriate rodent model of AMR, testing the hypothesis that treatment of the donor organ with a membrane-localizing biological inhibitor of thrombin could prevent the key manifestations of AMR, increasing graft survival, improving renal function, and reducing renal tissue injury.
Materials and Methods

Animals
All animals were purchased from Charles River (Kent, UK). Animals used in this project were inbred male dark agouti (DA) (RT1 a ) rats, weighing approximately 150 g, used as skin and kidney donors. Inbred male Lewis (RT1 i ) rats, weighing approximately 200 g, were used as recipients. Animals had free access to standard rat chow and water. All procedures were carried out in accordance with a UK Home Office license for animal experimentation.
Skin transplantation
Based on a method from Guttmann (18) , Lewis recipients were preimmunized by sequential grafting of three full-thickness tail skin segments (~2 cm 2 ) from DA donors. The skin grafts were held in place by applying a skin adhesive gel (Germolene New Skin; Boots, UK, Nottingham, UK) and bandaged for 7 days, after which the bandages were removed. The first two skin transplants were separated by a 2-week interval, followed by a 4-week period (to allow Ig affinity maturation). At 7-10 days after the third skin graft, the Lewis recipients received a DA kidney graft.
Rat renal transplantation
Rat renal transplantation was carried out as described previously (7). The donor and the recipient preparations took place simultaneously, thus minimizing the period of donor organ ischemia. Bilateral native nephrectomies were performed, making the survival of the recipient dependent only on the transplanted kidney. Graft rejection was defined either by elevated blood urea nitrogen (BUN) levels (≥40 mmol/L) or signs of poor health necessitating termination of the experiment, or the spontaneous death of an animal, all accompanied by histological evidence of rejection. 
Therapeutic agents
. HLL was then conjugated with the cytotopic tail APT3146 [(N-a,N-d,bis-myristoyl Lys-Ser-Ser-Lys-Ser-Pro-Lys-Lys-Asp-AspLys-Lys-Pro-Gly-Asp-(S-2-pyridyldithio)Cys], mediated by disulfide interchange (5) . The conjugate has a mass of 4649 Da by time-of-flight mass spectrometry and was prepared by reaction of the two components in aqueous solution at pH~7.4 followed by further purification (19) . The component peptides were prepared using solid-phase synthesis by Cambridge Research Biochemicals, Billingham, UK (both components were also synthesized at scale by Almac Sciences, Craigavon, UK). Later variants of TLN have been prepared using different bridging chemistry and will be described elsewhere.
Inhibitory activity of TLN-1 against human thrombin in solution and when tethered to cells
Human plasma thrombin (T6884) and N-p-5 Tosyl-Gly-Pro-Arg-p-nitroanilide (T1637-substrate) were obtained from Sigma-Aldrich (Gillingham, UK). Stock solutions of 10 U/mL and 1 mmol/L, respectively, were prepared in 0.05 mol/L Tris-HCl, pH 7.5, 0.1 mol/L NaCl, and 0.5% bovine serum albumin (BSA) (20) . Reaction mixtures were prepared with buffer, thrombin (5 lL, 0.05 U) and substrate (100 lL, 125 nmol/L) to a final volume of 800 lL and incubated at 25°C. When TLN-1 (or control HLL) was included (at various doses), these were premixed with thrombin at 25°C for~7 min and the reaction was then initiated by the addition of substrate. Thrombincatalyzed hydrolysis of N-p-Tosyl-Gly-Pro-Arg-p-nitroanilide was monitored at 405 nm on a Spectramax Plus384 (Molecular Devices, Sunnyvale, CA). The velocity of thrombin-catalyzed reaction was plotted against substrate concentration values using GraphPad Prism5 software and fitting data with nonlinear data-matching option. For each substrate concentration assayed, the velocity of the enzyme reaction represented the slope of the linear phase, expressed as amount of product formed per time (A 405 vs. time). The K m of thrombin for N-p-Tosyl-Gly-Pro-Arg-p-nitroanilide substrate under these conditions was found to be 10.47 + 2 nmol/L.
Guinea pig red blood cells (RBCs) washed with gelatin-veronal buffer were incubated with TLN-1 (or HLL control) for 10 min at room temperature with gentle agitation. After several washes, the supernatant was discarded and the cell pellet was resuspended with gelatin-veronal buffer and thrombin in a final reaction volume of 460 lL. Cells were further incubated for 3 min at 37°C in a water bath before being gently pelleted via centrifugation and counted via microscopy. Thrombin activity in the supernatant was assessed as just described by the addition of T1637 substrate. Values were expressed as percentage of cell inhibition for a certain thrombin amount after subtracting values of HLL-treated cells and normalization for cell number.
Plasma re-calcification assay Nest, 1.5 9 10 5 human CD34-derived progenitor cells (21) (kind gift of N.
Levicar, Hammersmith Hospital) were suspended in 50 lL Tris-buffered saline and mixed with 100 lL of normal human plasma (Sigma) in glass tubes (Corning, NY). Then, 100 lL of 25 mmol/L CaCl 2 in Tris-buffered saline was added, and the tube was incubated at 37°C in a water baththe time for a fibrin clot to form was determined in triplicate, during which the tubes were continuously agitated by tilting. In some assays, cells were incubated with 200 lL of HLL or TLN-1 for 25-30 min at 4°C before washing twice and inclusion in the clotting assay.
In situ perfusion with TLN-1
Intrarenal perfusion with TLN-1 (2 lmol/L) was based on a previously described protocol (6) . TLN-1 was dissolved in 5 mL of Soltran perfusion solution (Baxter Healthcare Ltd, Newbury, Berkshire, UK) perfused into the renal artery (1 mL/min over 5 min) and left to dwell for 10 min before flushing with 5 mL of Soltran to wash out unbound TLN-1. The donor kidney was then excised and immediately transplanted into the recipient. Any bleeding from the anastomosis was controlled with the use of Surgicel absorbable hemostat (Ethicon, Somerville, NJ) and gentle pressure.
Collection of blood and extraction of serum
Blood samples were collected before and after renal transplantation at appropriate time points via tail vein sampling. For serum preparation, whole blood was centrifuged twice for 15 min at 14 000 rpm. Serum samples taken before renal transplantation were used to assess alloantibody titer. Posttransplantation, renal function was assessed by daily estimation of BUN by using a standard urease kit (BUN Infinity, Fisher Scientific, Loughborough, UK), following the manufacturer's instructions.
Terminal blood samples were collected via cardiac puncture.
Rat splenocyte extraction
Rat splenocytes were obtained via disruption of fresh spleen through a 70-lm sieve into sterile phosphate-buffered saline (PBS). The cells were centrifuged and incubated with 5 mL of RBC lysis buffer for 5 min on ice. Lysis was stopped by adding PBS/2% fetal calf serum. The spleen cells were either resuspended in RPMI 1640 (Sigma) or frozen in DMSO (Sigma) in cryogenic vials (Nalgene, UK) and stored in liquid nitrogen. 
Detection of alloreactive IgG
Assessment of renal pathology
Transplanted kidneys removed at appropriate time points were transferred to 4% paraformaldehyde. Paraffin-embedded tissue was cut into 2-lm sections and stained with Martius Scarlet Blue (MSB).
Statistical analyses
Values were compared by using the Student t-test. Survival curves were compared by using a log-rank test and depicted by using Kaplan-Meier plots. A difference was considered significant when p < 0.05. 
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Results
TLN-1 exhibits membrane-localized inhibition of thrombin and clotting
The structure of TLN-1 is shown in Figure 1(A) . Guinea pig RBCs were incubated in a solution of TLN-1 (1 lmol/ L), during which TLN-1 was absorbed onto the RBC surfaces, so that after washing, the RBCs were able to specifically remove 0.05 U of exogenously added thrombin from solution ( Figure 1B) . In contrast, RBCs incubated with control HLL peptide (see Methods) bound no active HLL, such that after washing, the RBCs were unable to absorb any thrombin. Evidence of nonspecific interaction of thrombin with RBC membrane was not detected in these experiments (data not shown). Dose titration of thrombin revealed that 1 lmol/L) TLN-1 applied to RBCs could remove 80% of 0.4 U exogenously added thrombin, whereas dose titration of TLN-1 on the RBCs revealed that 0.1 lmol/L removed 84% of 0.05 U thrombin (data not shown). These data allowed the calculation of a thrombin inhibitory capacity of about 90% for 0.1 U/ 10 4 cells exposed to 1 lmol/L TLN-1 (typically 1-2 units of thrombin will clot 1 mL of plasma).
The functional importance of this interaction between TLN-1 and cell membranes is shown in Figure 1 they expressed human thrombin factor [data not shown]), compared with the clotting times observed in glass tubes when no cells were present. Preincubation of cells with TLN-1, followed by washing, completely abolished this procoagulant activity but did not inhibit clotting induced by the glass tubes. In contrast, HLL used in equimolar amounts as the TLN-1 and added to the clotting assay caused significant inhibition of all clotting activity, not just that associated with the presence of the CD34 + cells.
These data show that TLN-1 binds avidly to cell membranes, binds thrombin and removes it from solution, and exhibits anticoagulant activity selectively at the surface of cells to which it has bound.
Impact of TLN-1 on intragraft thrombosis and graft survival in a sensitized rat renal allograft model of AMR Flow cytometric assessment of DA splenocytes incubated with serum from Lewis rats sensitized by three DA skin grafts revealed high levels of circulating anti-DA IgG (data not shown). These presensitized animals rejected unmodified DA renal allografts with a median survival time (MST) of 1.8 days, compared with control nonsensitized Lewis rats, which rejected with a MST of 5.6 days (Figure 2A ).
Perfusion of DA kidneys pretransplantation with Soltran alone had no impact on survival time ( Figure 2B ), and rat recipients of these kidneys developed a rapid rise in BUN (Figures 2C and D) . Histological examination of kidneys harvested at time of rejection revealed florid features of AMR, with 50% of glomeruli demonstrating thrombosis (Figures 3 and 4) , significant interstitial hemorrhage and infarction of tubules (Figures 3 and 5) , and a prominent neutrophil peritubular capillaritis ( Figure 5 ).
In contrast, perfusion of DA kidneys pretransplantation with TLN-1 caused a significant prolongation of graft survival, similar to that seen in nonsensitized animals ( kidneys showed a prominent cellular infiltrate, in contrast to the paucity of cells seen in Soltran-perfused kidneys (Figures 3 and 4) , and although there were signs of AMR in TLN-1 kidneys, including a marked peritubular capillaritis ( Figure 5 ), the proportion of glomeruli showing thrombosis was reduced and the thrombosis seen tended to be segmental (Figure 4) . With the application of local methods of hemostasis (see Methods), there was no evidence of bleeding from the anastomosis in any of the TLN-1-treated grafts, nor of any systemic bleeding tendency in recipients of TLN-1-treated organs.
These data indicate that preperfusion of transplanted kidneys with TLN-1 has a significant impact on the mode and timing of rejection in these highly sensitized rats, characterized by inhibition of thrombosis and prevention of infarction, thus allowing time for significant cellular infiltration and the onset of cell-mediated rejection.
Discussion
The results presented here demonstrate that a novel compound generated by conjugating a potent direct thrombin inhibitor to a membrane-localizing entity is capable of binding to cell membranes, on which it can selectively capture (and inactivate) thrombin from the milieu and inhibit any procoagulant properties of the cell surface, without apparent impact on clotting induced beyond the antithrombin-treated cell surface. Moreover, perfusion of rodent kidney grafts before transplantation endowed them with a resistance to the manifestations of AMR, without any overt features associated with systemic anticoagulation. In particular, the impact on intragraft thrombosis was substantial, in terms of both the number of glomeruli that displayed no thrombosis and the amount of thrombus in that minority of glomeruli with thrombosis. Graft survival was extended to that seen in nonsensitized individuals and was accompanied by a significant cellular infiltrate and extensive tubulitis, consistent with the perception that cell-mediated immune mechanisms contributed to rejection in TLN-1-treated organs.
These results are reminiscent of those we presented previously (11), using a nonsensitized xenogeneic model system in which membrane-tethered anticoagulants were expressed transgenically on the endothelium of mouse hearts transplanted into rats. Those hearts were rejected by cell-mediated mechanisms despite the presence of high-titer anti-mouse antibodies and were completely resistant to intravascular thrombosis, consequent on sustained and stable expression of a hirudin-based construct by graft endothelial cells. In these new experiments, the effective residence time of TLN-1 on the graft endothelium is probably about 24 h (unpublished data), so it is surprising that the functional impact was so marked, but it illustrates the clinical therapeutic potential of TLN-1 (and later derivatives, unpublished data) in situations where a human donor organ is at risk of thrombosis, including after desensitisation to remove donor-specific HLA antibodies.
Thrombin plays an important role in AMR, not only via generation of fibrin to form occlusive thrombus but also through other mechanisms, including amplification of the complement cascade via several different routes (22, 23) and direct activation of graft endothelial cells via protease-activated receptor signaling (24) , which has been shown to be important for local chemokine gradient generation and leukocyte recruitment in the context of AMR (25) . Effective control of these nonthrombotic manifestations of thrombin is difficult to achieve using systemic anticoagulants, because of the risk of bleeding associated with the high doses required to maintain inhibition of coagulation proteases at cell membranes (26) . Our approach of tethering high concentrations of anticoagulant at the endothelial surface overcomes this potential problem, and it is noteworthy that our results were achieved without significant bleeding from the surgical anastomoses, although local measures, including surgical dressings and pressure, were necessary. Studies addressing the impact of TLN-1 on complement activation and protease activated receptor signaling will be reported elsewhere. In summary, the data presented here show that loading of the donor kidney with the novel membrane-adherent antithrombin TLN-1 can prevent thrombosis of the graft vasculature without the need for systemic anticoagulation. TLN-1 and its method of use are both translatable to clinical investigation, and our current work involves developmental chemistry and toxicology studies to enable subsequent evaluation in phase 1 and 2 studies involving transplant patients at high risk of thrombosis. We envisage that transplant surgery performed using a functionally anticoagulated organ without inducing a coagulation defect in the recipient would represent a significant medical advance. In a markedly prothrombotic environment, the risk of graft thrombosis will therefore be significantly reduced, at least for the likely duration that the tailed anticoagulant remains on the surface of the endothelial cell.
